Key result
TM-ViV linked to an absolute ~26% reduction in significant tricuspid regurgitation at 1 month.
Why the study?
The evolution of concomitant tricuspid regurgitation after transcatheter mitral valve-in-valve replacement is poorly characterized.
Does transcatheter mitral valve-in-valve replacement improve tricuspid regurgitation in high-risk patients with previous mitral valve surgery?
Cohort (n=96)
No
Does transcatheter mitral valve-in-valve replacement improve tricuspid regurgitation in high-risk patients with previous mitral valve surgery?
Transcatheter mitral valve-in-valve replacement effectively reduces the degree of concomitant tricuspid regurgitation in the majority of high-risk patients at midterm follow-up, suggesting that routine concomitant tricuspid intervention might not always be required in this setting.
Objective: The evolution of concomitant tricuspid regurgitation (TR) after transcatheter mitral valve-in-valve replacement (TM-ViV) is poorly characterized. Therefore, we aimed to analyze the midterm changes in TR following TM-ViV at our center. Methods: Clinical data of patients who underwent TM-ViV at Guangdong Provincial People's Hospital was retrospectively analyzed. In total, 96 patients underwent TM-ViV between April 2020 and October 2023. Conclusions: After TM-ViV surgery, the degree of TR decreased in a majority of patients who had moderate or severe TR preoperatively at midterm follow-up. However, due to limited statistical power, our exploratory analysis could not establish an association between preoperative TR and midterm mortality. Therefore, the prognostic influence of TR severity in this setting remains uncertain and requires validation in future studies.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) conducted a cohort in Prosthetic mitral valve dysfunction with concomitant tricuspid regurgitation (n=96). Transcatheter mitral valve-in-valve replacement was evaluated on Proportion of patients with moderate or severe tricuspid regurgitation at 1 month postoperatively (p=<0.001). Transcatheter mitral valve-in-valve replacement significantly reduced the proportion of patients with moderate or severe tricuspid regurgitation from 72.9% preoperatively to 47.3% at 1 month postoperatively (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: